4 recruiting, 1 completed, 1 terminated, 1 unknown. 7 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 4, Completed 1, Terminated 1, Unknown 1 |
| Phase 2 | 6 | Recruiting 4, Terminated 1, Unknown 1 |
Follow Locally Advanced: new trials by email Literature Review of Locally Advanced trials Research Report on Locally Advanced
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) AVZO-103, Combination Agent - Solid Tumor Cancer, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 355 | 2025-10-02 | 2026-10-05 |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) AVZO-1418, Combination Agent 1, Combination Agent 2 - Solid Tumor Cancer, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 480 | 2025-06-04 | 2026-10-16 |
| A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer REC-1245 - Unresectable, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Recursion Pharmaceuticals Inc. | 170 | 2024-11-21 | 2026-08-20 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
| Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors IMC-001 - Solid Tumor, Metastasis | Phase 1 | Completed | ImmuneOncia Therapeutics Inc. | 15 | 2018-03-22 | 2020-05-28 |
| Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma Palbociclib, Cetuximab, Intensity Modulated Radiation Therapy - Head and Neck Cancer, Locally Advanced | Phase 1 / Phase 2 | Unknown | Mahidol University | 27 | 2017-07-19 | 2024-03-15 |
| QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors AMG 479, AMG 655 - Colorectal Cancer, Locally Advanced | Phase 1 / Phase 2 | Terminated | NantCell, Inc. | 89 | 2009-01-16 | 2024-08-20 |
Neoplasm Metastasis (5) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Lung Neoplasms (2) · Ovarian Neoplasms (2) · Small Cell Lung Carcinoma (2) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma (1) · Endometrial Neoplasms (1) · Gallbladder Neoplasms (1) · Lymphoma (1) · Nasopharyngeal Neoplasms (1) · Neoplasms (1)
Neoplasms (6) · Neoplastic Processes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Neoplasms by Site (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Lung Diseases (3) · Neoplasms by Histologic Type (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Adnexal Diseases (2)
Cetuximab (1) · IMC-001 (1) · Radiotherapy, Intensity-Modulated (1) · conatumumab (1) · ganitumab (1) · palbociclib (1) · pembrolizumab (1)
Avenzo Therapeutics, Inc. (2) · ImmuneOncia Therapeutics Inc. (1) · Mahidol University (1) · NantCell, Inc. (1) · PMV Pharmaceuticals, Inc (1) · Recursion Pharmaceuticals Inc. (1)
United States (4) · South Korea (2) · Australia (1) · Canada (1) · China (1) · France (1) · Germany (1) · Italy (1) · Singapore (1) · Spain (1) · Thailand (1) · United Kingdom (1)
Marc Fellous, MD (1) · Nuttapong Ngamphaiboon, MD (1) · Yun Jeong Song, CMO/CEO (1)
PMID 34268711, PMID 37982827, PMID 40543428, PMID 40932470, PMID 41740031